|
|
||||||||
From the Section on Myelin Chemistry, Laboratory of Cerebral Metabolism, National Institute of Mental Health, Bethesda, Maryland 20014, and the Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98195
Abstract
Homologous myelin basic protein has been used successfully for treatment of experimental allergic encephalomyelitis (EAE) in NIH and strain 13 guinea pigs. Response of strain 13 guinea pigs to both induction and treatment of EAE was more consistent than response of outbred, NIH guinea pigs. Serum levels of antibasic protein antibody were related to the amount of mycobacteria used for sensitization rather than to disease severity or success of treatment.
Footnotes
1 Supported by Grant 828-A-4 from the National Multiple Sclerosis Society.
2 Supported in part by Research Grant NS-03147-12 from the National Institute of Neurological Diseases and Stroke, United States Public Health Service, and by Research Grant 427-E-12 from the National Multiple Sclerosis Society.
This article has been cited by other articles:
![]() |
A Gaur, B Wiers, A Liu, J Rothbard, and C. Fathman Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy Science, November 27, 1992; 258(5087): 1491 - 1494. [Abstract] [PDF] |
||||
![]() |
B. F. Driscoll, A. J. Kramer, and M. W. Kies Myelin Basic Protein: Location of Multiple Independent Antigenic Regions Science, April 5, 1974; 184(4132): 73 - 75. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |